<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/815094/000119312522311074/d353287d8k.htm>Download 8-K Special Filing Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/815094/000119312522311074/0001193125-22-311074-index.htm>Original filing index</a>
                        </div>

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Form 8-K - Current report - Item 2.01 Item 3.01 Item 3.03 Item 5.01 Item 5.02 Item 5.03 Item 9.01

Abiomed Inc.

Announcement: ABMD 8-K Special Filing

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/815094/000095017022021880/abmd-20220930.htm>Download 10-Q Quarterly Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/815094/000095017022021880/0000950170-22-021880-index.htm>Original filing index</a>
                        </div>

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ABIOMED Inc. Performance & Outlook Analysis
Current Analysis:
ABIOMED Inc. is a provider of medical devices that provide circulatory support and oxygenation. The company has seen success in expanding its direct sales activities in international markets, and has been able to maintain profitability at levels achieved in recent years. It has also been successful in developing and commercializing new products and acquiring desirable companies, products and technologies. The company is also facing risks such as inventory write-downs and other costs due to product quality issues, as well as risks and liabilities associated with acquisitions of other companies or businesses. The company is also impacted by the ongoing COVID-19 pandemic, which has adversely impacted and is likely to further adversely impact its business and markets.

Forward-Looking Analysis:
Going forward, ABIOMED Inc. faces potential risks such as fluctuations in foreign currency exchange rates and inflation, climate change, and corporate social responsibility and sustainability matters. The company also faces the risk of increased product liability claims and impact on its reputation and financial results, as well as changes in healthcare policy and reimbursement systems in the US and abroad. Additionally, the company is also subject to ongoing regulatory review, and risks relating to its shares of common stock, including market price volatility. The company is currently in the process of a merger with Johnson and Johnson, which is subject to certain conditions and risks such as the potential for dilution to its stockholders’ ownership interests and the failure to satisfy or waive the conditions to consummation of the merger. The outcome of these risks and opportunities will determine the future performance of the company.

Announcement: ABMD 10-Q Quarterly Report

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/815094/000095017022020707/abmd-20221101.htm>Download 8-K Special Filing Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/815094/000095017022020707/0000950170-22-020707-index.htm>Original filing index</a>
                        </div>

Form 8-K - Current report - Item 2.02 Item 9.01

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/815094/000119312522274497/d395522d8k.htm>Download 8-K Special Filing Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/815094/000119312522274497/0001193125-22-274497-index.htm>Original filing index</a>
                        </div>

Form 8-K - Current report - Item 1.01 Item 5.02 Item 5.03 Item 7.01 Item 9.01

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/815094/000095017022017121/abmd-20220810.htm>Download 8-K Special Filing Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/815094/000095017022017121/0000950170-22-017121-index.htm>Original filing index</a>
                        </div>

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/815094/000095017022014795/abmd-20220630.htm>Download 10-Q Quarterly Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/815094/000095017022014795/0000950170-22-014795-index.htm>Original filing index</a>
                        </div>

ABIOMED INC: Analyzing Financial Performance & Looking Ahead 
Current Analysis:
ABIOMED INC is a provider of medical devices that provide circulatory support and oxygenation. During the period, the company experienced an increase in demand for its products as a result of the COVID-19 pandemic and continued to offer onsite COVID-19 testing and vaccinations in order to maintain a safe working environment. The company has also faced risks and uncertainties related to foreign currency exchange rates, inflation, healthcare policy and reimbursement systems, inventory write-downs and product liability suits.

Forward-Looking Analysis:
Looking ahead, ABIOMED INC will continue to face risks and uncertainties related to the COVID-19 pandemic, government interventions to reduce the spread of the virus, foreign currency exchange rates, inflation, and healthcare policy and reimbursement systems. The company will also need to continue to successfully compete against its existing and potential competitors, develop and commercialize new products and acquire desirable companies, products or technologies. Additionally, the company needs to maintain compliance with regulatory requirements and continuing regulatory review, as well as attract and retain key personnel. ABIOMED INC will need to successfully meet these challenges in order to sustain profitability at levels achieved in recent years.